Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 50, 2011, Pages 20002-20007

  Hettmer, Simone ^a,b,c,d,e,f   Liu, Jianing ^a,b,c,d   Miller, Christine M ^a,b,c,d   Lindsay, Melissa C ^a,b,c,d   Sparks, Cynthia A ^g   Guertin, David A ^g   Bronson, Roderick T ^h   Langenau, David M ^c,i   Wagers, Amy J ^a,b,c,d  

^a HARVARD UNIVERSITY   (United States)

^b Harvard University   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d JOSLIN DIABETES CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^h TUFTS UNIVERSITY   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer stem cell; Preclinical screening platform; Sarcoma oncogenes

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; GLYCINE; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; RAS PROTEIN; VALINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CELL ISOLATION; CELL LINEAGE; CONTROLLED STUDY; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC DISORDER; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MESENCHYME CELL; MOUSE; MUSCLE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEPTOR UPREGULATION; RHABDOMYOSARCOMA; SARCOMA; SIGNAL TRANSDUCTION; SKELETAL MUSCLE SATELLITE CELL; SOFT TISSUE SARCOMA; STEM CELL; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT;

ANIMALS; CELL LINEAGE; CELL PROLIFERATION; CELL SEPARATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MUSCLE CELLS; MUSCLE DEVELOPMENT; MUSCLE FIBERS, SKELETAL; MUSCLE NEOPLASMS; MUSCLE, SKELETAL; RAS PROTEINS; RATS; SARCOMA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84055178989     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1111733108     Document Type: Article

References (53)

1. Clark MA, Fisher C, Judson I, Thomas JM (2005) Soft-tissue sarcomas in adults. N Engl J Med 353(21):701-711. (Pubitemid 41175678)
2. Parham DM, Ellison DA (2006) Rhabdomyosarcomas in adults and children: An update. Arch Pathol Lab Med 130:1454-1465. (Pubitemid 44520712)
3. Rubin BP, et al. (2011) Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell 19(2):177-191.
4. Fletcher CD, Gustafson P, Rydholm A, Willén H, Akerman M (2001) Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: Prognostic relevance of subclassification. J Clin Oncol 19:3045-3050. (Pubitemid 32565442)
5. Morotti RA, et al.; Children's Oncology Group (2006) An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: The Children's Oncology Group experience. Am J Surg Pathol 30:962-968. (Pubitemid 44264944)
6. Langenau DM, et al. (2007) Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 21:1382-1395. (Pubitemid 46871041)
7. Tiffin N, Williams RD, Shipley J, Pritchard-Jones K (2003) PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br J Cancer 89:327-332. (Pubitemid 36976324)
8. Keller C, et al. (2004) Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: Cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 18:2614-2626. (Pubitemid 39453101)
9. Ren YX, et al. (2008) Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 68:6587-6597.
10. Hettmer S, Wagers AJ (2010) Muscling in: Uncovering the origins of rhabdomyosarcoma. Nat Med 16(2):171-173.
11. Martinelli S, et al. (2009) RAS signaling dysregulation in human embryonal Rhabdomyosarcoma. Genes Chromosomes Cancer 48:975-982.
12. Stratton MR, Fisher C, Gusterson BA, Cooper CS (1989) Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res 49:6324-6327. (Pubitemid 20000931)
13. Yoo J, Robinson RA, Lee JY (1999) H-ras and K-ras gene mutations in primary human soft tissue sarcoma: Concomitant mutations of the ras genes. Mod Pathol 12:775-780. (Pubitemid 29383880)
14. Tsumura H, Yoshida T, Saito H, Imanaka-Yoshida K, Suzuki N (2006) Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene 25:7673-7679. (Pubitemid 44967962)
15. Serrano M, et al. (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell 85(1):27-37. (Pubitemid 26116804)
16. Kohashi K, et al. (2008) Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: Special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. J Cancer Res Clin Oncol 134:1097-1103.
17. Obana K, et al. (2003) Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid tumors. Int J Oncol 23:1151-1157.
18. Chen Y, et al. (2007) Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression. Genes Chromosomes Cancer 46:348-358. (Pubitemid 46411326)
19. Houghton PJ, et al. (2008) Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50:799-805. (Pubitemid 351354788)
20. Marampon F, et al. (2009) MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Mol Cancer Ther 8:543-551.
21. Petricoin EF, 3rd, et al. (2007) Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 67:3431-3440.
22. Wagers AJ, Conboy IM (2005) Cellular and molecular signatures of muscle regeneration: Current concepts and controversies in adult myogenesis. Cell 122:659-667. (Pubitemid 41242632)
23. Cerletti M, et al. (2008) Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. Cell 134(1):37-47. (Pubitemid 351905744)
24. Sherwood RI, et al. (2004) Isolation of adult mouse myogenic progenitors: Functional heterogeneity of cells within and engrafting skeletal muscle. Cell 119(4):543-554. (Pubitemid 39482353)
25. Joe AW, et al. (2010) Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat Cell Biol 12(2):153-163.
26. Schulz TJ, et al. (2011) Identification of inducible brown adipocyte progenitors residing in skeletal muscle and white fat. Proc Natl Acad Sci USA 108(1):143-148.
27. Uezumi A, Fukada S, Yamamoto N, Takeda S, Tsuchida K (2010) Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat Cell Biol 12(2):143-152.
28. Bonnefoix T, Bonnefoix P, Verdiel P, Sotto JJ (1996) Fitting limiting dilution experiments with generalized linear models results in a test of the single-hit Poisson assumption. J Immunol Methods 194(2):113-119. (Pubitemid 26341983)
29. Thorrez L, et al. (2008) Using ribosomal protein genes as reference: A tale of caution. PLoS One 3(3):e1854.
30. Nishijo K, et al. (2009) Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res 69:2902-2911.
31. Mito JK, et al. (2009) Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS ONE 4:e8075.
32. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR (2007) A conditional mouse model of synovial sarcoma: Insights into a myogenic origin. Cancer Cell 11:375-388. (Pubitemid 46518310)
33. Davicioni E, et al. (2009) Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: A report from the Children's Oncology Group. Am J Pathol 174:550-564.
34. Kang PB, et al. (2005) Variations in gene expression among different types of human skeletal muscle. Muscle Nerve 32:483-491. (Pubitemid 41395981)
35. Bild AH, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357. (Pubitemid 43128862)
36. Chang JT, et al. (2009) A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell 34(1):104-114.
37. Hoeflich KP, et al. (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15:4649-4664.
38. Favata MF, et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273:18623-18632. (Pubitemid 28334795)
39. Koren I, Reem E, Kimchi A (2010) DAP1, a novel substrate of mTOR, negatively regulates autophagy. Curr Biol 20:1093-1098.
40. Buller CL, et al. (2008) A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol 295:C836-C843.
41. Shapira M, Kakiashvili E, Rosenberg T, Hershko DD (2006) The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Res 8:R46.
42. Karam AK, et al. (2010) Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken) 67:535-544.
43. She P, et al. (2007) Disruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. Cell Metab 6:181-194. (Pubitemid 47324140)
44. Thoreen CC, et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284:8023-8032.
45. Agulnik M (2011) New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma. Cancer, 10.1002/cncr.26361.
46. Linardic CM, Downie DL, Qualman S, Bentley RC, Counter CM (2005) Genetic modeling of human rhabdomyosarcoma. Cancer Res 65:4490-4495. (Pubitemid 40740781)
47. Stubbs MC, Armstrong SA (2007) Therapeutic implications of leukemia stem cell development. Clin Cancer Res 13:3439-3442. (Pubitemid 46955102)
48. Miura K, et al. (2009) Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 27:743-745.
49. Polo JM, et al. (2010) Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 28:848-855.
50. Carneiro A, et al. (2009) Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: Different sides of a single coin? Lab Invest 89:668-675.
51. Yu Y, et al. (2004) Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 10(2):175-181. (Pubitemid 38524888)
52. Cen L, et al. (2007) PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer 97:785-791. (Pubitemid 47396297)
53. Jing E, Gesta S, Kahn CR (2007) SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab 6(2):105-114. (Pubitemid 47163621)